ACXP Acurx Pharmaceuticals Inc

$ACXP pathfinder started on Aug 3, and they've enrolled one patient. 2 months per patient enrollment rate which tracks their prior enrollment performance. It is a 20 patient study. So this will take 40 months at this rate. In 2025 they burned $ 7M. In 2024 they burned $ 10M during clinical trials. They have $ 10M cash on hand. So they won't have enough cash to finish this open label, single arm study, and if they did, it would be in 3.5 years. Luci and Friends will get another year of salary. Maybe 1.5 years if they do another dilution. Either way they will get delisted for going under $1, or going under $ 5M market cap. That is coming in the next few months based on current trends. RIP Ibezapolstat. FU LUCI

$ACXP signed a 12-month media series with New to The Street to broadcast monthly interviews on its antibiotic pipeline.

$ACXP looking for a position here. Looks like plague stocks might be good to get into right now.

$ACXP Back in April I predicted 3 patients enrolled by November. Well, they've only enrolled 1 patient by October. No way will he get 3 by November. And yet he will keep pretending until the music stops. Somehow Luci always finds a way to underdeliver. Hopefully he gets delisted sooner than later, before the cash is gone, so their remaining cash can go back to shareholders. FU Luci!

$ACXP "We continue to identify and pursue funding opportunities for our Phase 3 ASPIRE trial for the treatment of both acute CDI and a reduction of recurrence. We have several initiatives underway to this end and will report our progress in future updates."

$ACXP begins patient enrollment in its PATHFINDER Phase 2 trial of ibezapolstat for multiply-recurrent C. difficile infection.